MEDICAL: PHARMACY PHARMACEUTICAL PHARMACOLOGY: DRUG: ADVERSE EVENT: Risk
of Heart Failure With Use of Mitoxantrone (Novantrone) for Multiple
Sclerosis and Other Patients: Some Article Citations
This is a selection of published articles that discuss heart implications
and heart failure where Novantrone also known as Mitoxantrone have been
used for the treatment of Multiple Sclerosis.
Langer-Gould A. Moses HH. Murray TJ.
Strategies for managing the side effects of treatments for
multiple sclerosis.
Neurology.
63(11 Suppl 5):S35-41, 2004 Dec 14.
Kluza J. Marchetti P. Gallego MA. Lancel S. Fournier C.
Loyens A. Beauvillain JC. Bailly C.
Mitochondrial proliferation during apoptosis induced by
anticancer agents: effects of doxorubicin and mitoxantrone
on cancer and cardiac cells.
Oncogene.
23(42):7018-30, 2004 Sep 16.
Ghalie RG. Edan G. Laurent M. Mauch E. Eisenman S.
Hartung HP. Gonsette RE. Butine MD. Goodkin DE.
Cardiac adverse effects associated with mitoxantrone
(Novantrone) therapy in patients with MS.
Neurology.
59(6):909-13, 2002 Sep 24.
Koutinos G. Stathopoulos GP. Dontas I. Perrea-Kotsarelis D.
Couris E. Karayannacos PE. Deliconstantinos G.
The effect of doxorubicin and its analogue mitoxantrone on
cardiac muscle and on serum lipids: an experimental study.
Anticancer Research.
22(2A):815-20, 2002 Mar-Apr.
Herman EH. Zhang J. Rifai N. Lipshultz SE. Hasinoff BB.
Chadwick DP. Knapton A. Chai J. Ferrans VJ.
The use of serum levels of cardiac troponin T to compare
the protective activity of dexrazoxane against doxorubicin-
and mitoxantrone-induced cardiotoxicity.
Cancer Chemotherapy & Pharmacology.
48(4):297-304, 2001 Oct.
Gralow JR. Livingston RB.
University of Washington high-dose cyclophosphamide,
mitoxantrone, and etoposide experience in metastatic
breast cancer: unexpected cardiac toxicity.
Journal of Clinical Oncology.
19(18):3903-4, 2001 Sep 15.
Wang GX. Zhou XB. Eschenhagen T. Korth M.
Effects of mitoxantrone on action potential and membrane
currents in isolated cardiac myocytes.
British Journal of Pharmacology.
127(2):321-30, 1999 May.
Macquart-Moulin G. Viens P. Genre D. Bouscary ML.
Resbeut M. Gravis G. Camerlo J. Maraninchi D. Moatti JP.
Concomitant chemoradiotherapy for patients with nonmetastatic
breast carcinoma: side effects, quality of life, and organization.
Cancer.
85(10):2190-9, 1999 May 15.
Pectasides D. Tsavdaridis D. Aggouridaki C. Tsavdaridou V.
Visvikis A. Tsatalas K. Fountzilas G.
Effects on blood coagulation of adjuvant CNF
(cyclophosphamide, novantrone, 5-fluorouracil)
chemotherapy in stage II breast cancer patients.
Anticancer Research.
19(4C):3521-6, 1999 Jul-Aug.
Benjamin RS.
Rationale for the use of mitoxantrone in the older patient:
cardiac toxicity.
Seminars in Oncology.
22(1 Suppl 1):11-3, 1995 Feb.
Lewkow LM. Hooker JL. Movahed A.
Cardiac complications of intensive dose mitoxantrone and
cyclophosphamide with autologous bone marrow
transplantation in metastatic breast cancer.
International Journal of Cardiology.
34(3):273-6, 1992 Mar.
Janmohammed R. Milligan DW.
Mitoxantrone induced congestive heart failure in patients
previously treated with anthracyclines.
British Journal of Haematology.
71(2):292-3, 1989 Feb.
Posner LE. Dukart G. Goldberg J. Bernstein T. Cartwright K.
Mitoxantrone: an overview of safety and toxicity.
Investigational New Drugs.
3(2):123-32, 1985.
Pratt CB. Crom DB. Wallenberg J. Sanyal SK.
Miliauskas J. Sohlberg K.
Fatal congestive heart failure following mitoxantrone treatment in
two children previously treated with doxorubicin and cisplatin.
Cancer Treatment Reports.
67(1):85-8, 1983 Jan.
Smith IE. Mitoxantrone (novantrone): a review of experimental
and early clinical studies.
Cancer Treatment Reviews.
10(2):103-15, 1983 Jun.
Unverferth DV. Unverferth BJ. Balcerzak SP.
Bashore TA. Neidhart JA.
Cardiac evaluation of mitoxantrone.
Cancer Treatment Reports.
67(4):343-50, 1983 Apr.
The US Novantrone [mitoxantrone] label has been revised to state
that cardiac monitoring should be performed.
Reactions Weekly.
1053:2, May 28, 2005.
Goffette, S.; Van Pesch, V.; Sindic, C. J. M.
Severe delayed heart failure in three MS patients previously treated
with mitoxantrone: P1325.
European Journal of Neurology
Supplement. 11 Supplement 2:121, September 2004.
Goodin, D.S. MD; Arnason, B.G. MD;
Coyle, P.K. MD, FAAN; Frohman, E.M. MD;
Paty, D.W. MD, FAAN
The use of mitoxantrone (Novantrone) for the treatment of
multiple sclerosis: Report of the Therapeutics and
Technology Assessment Subcommittee of the American
Academy of Neurology.
Neurology.
61(10):1332-1338, November 25, 2003.
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary
progressive multiple sclerosis
Jagannadha R Avasarala1, Anne H Cross1, David B Clifford1, Barry A
Singer1, Barry A Siegel2,
and Elliot E Abbey3
1Department of Neurology, 2Mallinckrodt Institute of Radiology,
3Department of Medicine, Washington University School
of Medicine, St Louis, MO 63110, USA
<http://paincenter.wustl.edu/c/BasicResearch/documents/Cliffordmultscler2003.pdf\
>
Mito xantro ne is a recently appro ved drug for patients with secondary
pro gressive multiple sclero sis (SPMS). However, cardiac side effects
limit Mitoxantro ne use in SPMS and its lifetime cumulative dose should
not exceed 140 mg/m2. A dditionally, Mitoxantrone is contraindicated for
use in SPMS patients with a baseline left ventr icular ejectio n fractio n
(LVEF) of /50%. The goal of this study was to monito r LVEF more
frequently than ordinarily recommended since exper ience with Mitoxantrone
use in SPMS patients is limited. A n unexpected decline in LVEF in one of
the SPMS patients being treated with Mitoxantro ne prompted further
investigation into this finding. In our clinic, 47 patients on Mitoxantro
ne were followed prospectively; 28 of 47 patients had received a minimum
of three doses and underwent a repeat LVEF evaluatio n prior to their four
th dose of Mito xantro ne. Of these 28 patients, five of 28 (17.8%) had a
significant decline in LVEF from baseline. It is suggested that more
stringent cardiac monito ring guidelines than current Food and Drug A
dministration (FDA ) recommendatio ns be used to avert potential cardiac
complications in SPMS patients on Mito xantro ne.
Multiple Sclerosis (2003) 9, 59 /62
Key w o r d s: cardiotoxicity; left ventricular function; Mitoxantrone;
monitor ing; radionuclide ventriculography; secondary
progressive multiple sclerosis
Acute heart failure in a patient treated by mitoxantrone
for multiple slerosis
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&list_uids=14978418&dopt=Abstract>
Rev Neurol (Paris). 2003 Dec;159(12):1169-72
Feuillet L, Guedj E, Eusebio A, Malikova I, Pelletier J, Mundler O, Ali
Cherif A.
Service de Neurologie.
Risks of Cardiac Problems from Mitoxantrone in
Treating MS Outlined
<http://www.aan.com/press/press/index.cfm?
fuseaction=release.view&release=66>
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
[log in to unmask]
<http://groups.yahoo.com/group/net-gold>
<http://www.edu-cyberpg.com/ringleaders/davidd.html>
<http://www.kovacs.com/medref-l/medref-l.html>
<http://listserv.temple.edu/archives/net-gold.html>
<http://www.LIFEofFlorida.org>
World Business Community Advisor
<http://www.WorldBusinessCommunity.org>
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
[log in to unmask]
<http://groups.yahoo.com/group/net-gold>
<http://www.edu-cyberpg.com/ringleaders/davidd.html>
<http://www.kovacs.com/medref-l/medref-l.html>
<http://listserv.temple.edu/archives/net-gold.html>
<http://www.LIFEofFlorida.org>
World Business Community Advisor
<http://www.WorldBusinessCommunity.org>
________________End of message______________________
Archives and tools for the Disability-Research Discussion List
are now located at:
www.jiscmail.ac.uk/lists/disability-research.html
You can JOIN or LEAVE the list from this web page.
|
